Acorda Therapeutics Cdt Stock
Pros and Cons of Acorda Therapeutics Cdt in the next few years
Pros
?
M***** P*******
?
S********** s********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Acorda Therapeutics Cdt vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Acorda Therapeutics Cdt | - | - | - | - | - | - | - |
Ardelyx Inc. | -10.570% | -13.495% | 3.392% | 89.573% | 7.578% | 9.088% | - |
Evolus Inc | -5.830% | -8.130% | 6.604% | 32.164% | 24.862% | 51.678% | - |
Salarius Pharmaceuticals Inc. | 5.580% | 0.971% | -2.804% | -69.412% | -25.045% | -98.384% | -99.993% |
Comments
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat